CSIMarket
 
Enliven Therapeutics Inc   (ELVN)
Other Ticker:  
 
 
Price: $17.5600 $1.03 6.231%
Day's High: $17.61 Week Perf: 5.97 %
Day's Low: $ 16.31 30 Day Perf: 7.47 %
Volume (M): 78 52 Wk High: $ 24.80
Volume (M$): $ 1,375 52 Wk Avg: $16.75
Open: $16.31 52 Wk Low: $9.80



 Market Capitalization (Millions $) 721
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 37
 Capital Exp. (TTM) (Millions $) 0

Enliven Therapeutics Inc
Enliven Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for a variety of diseases and conditions. The company employs cutting-edge technologies and research methods to discover, design, and develop new medications. Enliven Therapeutics Inc aims to improve patient outcomes and quality of life by addressing unmet medical needs. Their team of scientists, researchers, and medical professionals work diligently to create safe and effective treatments that can positively impact the lives of patients.


   Company Address: 6200 Lookout Road Boulder 80301 CO
   Company Phone Number: 647-8519   Stock Exchange / Ticker: NASDAQ ELVN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Enliven Therapeutics Inc

Restructuring Challenges Major Pharmaceutical Preparations Company, Leading to Operating Struggles in Fiscal Third Quarter of 20232.

Enliven Therapeutics Inc, a smaller corporation in the Major Pharmaceutical Preparations industry, recently reported a significant operating shortfall of $-24.248 million for the third quarter of 2023. This news has caused concerns among investors who were hoping for new revenue streams to emerge soon. However, the market seems less interested in the company's current proficiency in the industry.
In their pursuit of establishing lucrative revenue streams, companies often go through challenging periods. One such instance was the fiscal interval ending on September 30, 2023, where the shortfalls expanded to $-20.769 million. This suggests that Enliven Therapeutics Inc may be facing difficulties in generating sufficient profits and sustaining growth.

Enliven Therapeutics Inc

Enliven Therapeutics Inc Reports Contracted Operating Deficit in Q2 2023, Raising Concerns about Future Prospects



Enliven Therapeutics Inc, a company operating in the Major Pharmaceutical Preparations sector, recently disclosed its financial results for the second quarter of 2023. The report revealed a significant operating deficit that had contracted from the previous year. However, concerns have arisen regarding the absence of top-line growth and the notable increase in the net deficit. As investors await Enliven Therapeutics Inc's next financial results, it is crucial to analyze how these factors might impact the company's future prospects.
Contracted Operating Deficit:
Enliven Therapeutics Inc faced an operating deficit of $-20.134 million in Q2 2023, a contraction from the previous year's figure of $-11.521 million. While this reduction may initially appear positive, it is essential to delve deeper into the reasons behind this operating deficit and the sustainability of its improvements.

Enliven Therapeutics Inc

Enliven Therapeutics Inc Reports Increasing Working Outlays in Q1 2023 amid Challenging Market Conditions

Investors in the Chemical Manufacturing industry are keeping a close eye on the January to March 31, 2023 reporting season, with several corporations announcing their respective numbers. One of the most notable updates has come from ELVN, which published an operating loss of $-16.418 million for the most recent fiscal period.
While ELVN has not yet shared its revenue figures for the same period, it's worth noting that the company's performance in the first quarter of 2022 resulted in an operating loss of $-14.661 million, offering a baseline for comparison.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com